When Laura Burns went to get her first Covid-19 shot last January, no one had warned her that the vaccines might not work for her. Burns, the recipient of a double-lung transplant in 2016, knew to be…
When Idera Pharmaceuticals flunked a Phase III melanoma trial with its Toll-like receptor 9 agonist tilsotolimod back in March, executives clung to the hope that separate trials in other cancers would…
The US government is shifting its distribution of mAb infusions to fight the coronavirus, deciding to go from supplying tens of thousands of doses of GlaxoSmithKline and Vir’s mAb treatment sotrovimab…
Though it’s already publicly traded in the US and Hong Kong, BeiGene went and triple-listed itself in Shanghai’s stock exchange as well. But early returns have reportedly been far from promising.…
After a post-marketing trial for Pfizer’s Xeljanz turned concerning safety results at the beginning of the year, thwarting the whole JAK class, the FDA is finally rolling out some new approvals — but…
A new biotech emerged from stealth and joined the Massachusetts biotech scene this morning, announcing its launch with a Series A for $10.5 million. Aramis Biosciences, founded back in 2018, had its…
Another factual information on the “Global Pharmaceutical Drug Delivery Market” has as of late added by CMI to its storehouse. This global research report offers an inside and out examination of various perspectives, for example, global market patterns, pieces of
Massachusetts biotech Keros Therapeutics now has a deal with Hansoh Healthtech, a Hansoh Pharmaceutical Group subsidiary, in the form of an exclusive license. The deal was announced earlier this week,…
After getting ditched by Roche a month ago, Atea is laying out a path forward for a failed COVID-19 med called AT-527, including a plan to conduct combination studies. Back in November, Roche cut ties…
NuVasive resumes global sales of scoliosis system with reinstated CE mark and new labeling
apark
Wed, 12/15/2021 – 11:25
